Literature DB >> 21597183

Suppression by fucoidan of liver fibrogenesis via the TGF-β/Smad pathway in protecting against oxidative stress.

Sang-Won Hong1, Kyung Hee Jung, Hee-Seung Lee, Hong-Mei Zheng, Myung-Joo Choi, Chongmu Lee, Soon-Sun Hong.   

Abstract

Fucoidan, a sulfated polysaccharide extracted from various types of brown seaweed, possesses a wide range of pharmacological properties. We investigated the protective effect of fucoidan on dimethylnitrosamine-induced liver fibrogenesis in rats and its mechanism. Liver fibrosis was induced by injecting DMN (10 mg/kg, 3 times per week, I.P.) for 4 weeks, and fucoidan was simultaneously administered (100 mg/kg, 3 times per week, P.O.). The anti-oxidative and anti-inflammatory effects of fucoidan were observed by relative mediators. Fucoidan improved liver fibrosis by inhibiting the expression of transforming growth factor beta 1 (TGF-β(1))/Smad3 and the tissue inhibitor of metalloproteinase 1 (TIMP-1), and increasing the expression of metalloproteinase-9 (MMP-9). Fucoidan also significantly decreased the accumulation of the extracellular matrix (ECM) and collagen. These results suggest that fucoidan had an anti-fibrotic effect, which was exerted by inhibiting the TGF-β/Smad pathway, as well as anti-oxidative and anti-inflammatory effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21597183     DOI: 10.1271/bbb.100599

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  13 in total

Review 1.  Bicuspid aortic valve aortopathy: genetics, pathophysiology and medical therapy.

Authors:  Nada Abdulkareem; Jeremy Smelt; Marjan Jahangiri
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-05-31

2.  Low molecular weight fucoidan ameliorates diabetic nephropathy via inhibiting epithelial-mesenchymal transition and fibrotic processes.

Authors:  Jihui Chen; Wentong Cui; Quanbin Zhang; Yingli Jia; Yi Sun; Lin Weng; Dali Luo; Hong Zhou; Baoxue Yang
Journal:  Am J Transl Res       Date:  2015-09-15       Impact factor: 4.060

3.  Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-β/Smad p53 pathway in rat model.

Authors:  Othman A Al-Shabanah; Abdulaziz M Aleisa; Mohamed M Hafez; Salim S Al-Rejaie; Abdulaziz A Al-Yahya; Saleh A Bakheet; Mohamed M Al-Harbi; Mohamed M Sayed-Ahmed
Journal:  Oxid Med Cell Longev       Date:  2012-04-30       Impact factor: 6.543

4.  Fucoidan from Fucus vesiculosus protects against alcohol-induced liver damage by modulating inflammatory mediators in mice and HepG2 cells.

Authors:  Jung Dae Lim; Sung Ryul Lee; Taeseong Kim; Seon-A Jang; Se Chan Kang; Hyun Jung Koo; Eunsoo Sohn; Jong Phil Bak; Seung Namkoong; Hyoung Kyu Kim; In Sung Song; Nari Kim; Eun-Hwa Sohn; Jin Han
Journal:  Mar Drugs       Date:  2015-02-16       Impact factor: 5.118

5.  Protective effect of fucoidan from Fucus vesiculosus on liver fibrosis via the TGF-β1/Smad pathway-mediated inhibition of extracellular matrix and autophagy.

Authors:  Jingjing Li; Kan Chen; Sainan Li; Jiao Feng; Tong Liu; Fan Wang; Rong Zhang; Shizan Xu; Yuqing Zhou; Shunfeng Zhou; Yujing Xia; Jie Lu; Yingqun Zhou; Chuanyong Guo
Journal:  Drug Des Devel Ther       Date:  2016-02-12       Impact factor: 4.162

6.  Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43.

Authors:  Yuri Cho; Jung-Hwan Yoon; Jeong-Ju Yoo; Minjong Lee; Dong Hyeon Lee; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Chung Yong Kim
Journal:  Acta Pharm Sin B       Date:  2015-11-18       Impact factor: 11.413

7.  Oligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression.

Authors:  Li-Mei Chen; Po-Yen Liu; Yen-An Chen; Hong-Yu Tseng; Pei-Chun Shen; Pai-An Hwang; Hsin-Ling Hsu
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

Review 8.  Fucoidan as a marine anticancer agent in preclinical development.

Authors:  Jong-Young Kwak
Journal:  Mar Drugs       Date:  2014-01-28       Impact factor: 5.118

Review 9.  Fucoidan as a Potential Therapeutic for Major Blinding Diseases--A Hypothesis.

Authors:  Alexa Klettner
Journal:  Mar Drugs       Date:  2016-02-03       Impact factor: 5.118

10.  The Ameliorative Effects of Fucoidan in Thioacetaide-Induced Liver Injury in Mice.

Authors:  Ming-Yang Tsai; Wei-Cheng Yang; Chuen-Fu Lin; Chao-Min Wang; Hsien-Yueh Liu; Chen-Si Lin; Jen-Wei Lin; Wei-Li Lin; Tzu-Chun Lin; Pei-Shan Fan; Kuo-Hsiang Hung; Yu-Wen Lu; Geng-Ruei Chang
Journal:  Molecules       Date:  2021-03-30       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.